Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/193129
Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Fibrosis is present in an important proportion of myocardial disorders. Injury activates cardiac fibroblasts, which deposit excess extracellular matrix, increasing tissue stiffness, impairing cardiac function, and leading to heart failure. Clinical therapies that directly target excessive fibrosis are limited, and more effective treatments are needed. Immunotherapy based on chimeric antigen receptor (CAR) T cells is a novel technique that redirects T lymphocytes toward specific antigens to eliminate the target cells. It is currently used in haematological cancers but has demonstrated efficacy in mouse models of hypertensive cardiac fibrosis, with activated fibroblasts as the target cells. CAR T cell therapy is associated with significant toxicities, but CAR natural killer cells can overcome efficacy and safety limitations. The use of CAR immunotherapy offers a potential alternative to current therapies for fibrosis reduction and restoration of cardiac function in patients with myocardial fibrosis.
Matèries
Matèries (anglès)
Citació
Citació
FERRER CURRIU, Gemma, SOLER BOTIJA, Carolina, CHARVATOVA, Sandra, MOTAIS, Benjamin, ROURA, Santiago, GÀLVEZ MONTÓN, Carolina, MONGUIÓ TORTAJADA, Marta, IBORRA EGEA, Oriol, EMDIN, Michele, LUPÓN, Josep, AIMO, Alberto, BAGÓ, Juli r., GENÍS, Antoni bayés. Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy. _Biomedicine & Pharmacotherapy_. 2023. Vol. 158, núm. 114061. [consulta: 24 de gener de 2026]. ISSN: 0753-3322. [Disponible a: https://hdl.handle.net/2445/193129]